Novanta . Tangible Equity Units Stock Earnings Reports

Novanta reported a strong start to 2026 with Q1 revenue up 10% reported and 3% organic, bookings up 37% YoY and a book-to-bill of 1.10. All businesses delivered year-over-year revenue growth and double-digit bookings growth. Key operational highlights: adjusted EBITDA grew 14% with a 70 bps margin expansion, adjusted EPS rose 9%, operating cash flow increased 63% YoY and cash flow conversion to net income exceeded 200%. New product revenue rose ~50% YoY and the Vitality Index reached ~27% of sales, driven by design wins and commercial momentum. End-market momentum is broad-based: Robotics & Automation (including GenAI-related applications), Advanced Surgery (insufflators, medical consumables), Precision Manufacturing (laser beam steering, metrology, semiconductor-related subsystems) and Precision Medicine (including the Keonn acquisition). Management estimates GenAI/data-center related exposure at ~15% of Q1 revenue and growing ~20% YoY. Near-term headwinds included a price/cost timing impact from rapidly changing tariffs, freight and material cost increases; management is implementing surcharges, price increases and cost actions plus regional manufacturing consolidations to recover gross margin in H2. Guidance: 2026 revenue raised to $1,040M–$1,055M (reported growth >7%, organic up to 6%), adjusted EBITDA reaffirmed at $245M–$250M, adjusted EPS $3.50–$3.65. Q2 revenue guide is $259M–$264M (organic growth 6%–8%); Q2 adjusted EBITDA $58M–$62M and adjusted EPS $0.81–$0.86. Balance sheet: net cash position (~$389M cash, gross debt $249M) and disciplined capital allocation with acquisitions prioritized but opportunistic buybacks continuing.